Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560397 | 0.89 | CYP1A2 (0.43) | ADORA2ACYP2D6 | |
| SCHEMBL12891462 | 0.84 | ADORA2A (0.47) | ADORA2ATPSAB1TPSD1TPSG1GRIN2B | |
| SCHEMBL559613 | 0.82 | GRIN2B (0.42) | ADORA2AGRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL559593 | 0.81 | ADORA2A (0.43) | ADORA2ATPSAB1TPSD1TPSG1GRIN2B | |
| SCHEMBL559730 | 0.79 | ADORA2A (0.43) | ADORA2A | |
| SCHEMBL559641 | 0.78 | ADORA2A (0.42) | ADORA2AGRIN2B | |
| SCHEMBL559756 | 0.78 | ADORA2A (0.46) | ADORA2AGRIN2B | |
| SCHEMBL559478 | 0.78 | ADORA2A (0.44) | ADORA2AGRIN2BCYP2C9 | |
| SCHEMBL13612212 | 0.77 | ADORA2A (0.56) | ADORA2A | |
| SCHEMBL1244971 | 0.77 | ADORA2A (0.56) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309774-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2012-12-06 | — | — | US | disclosed |
| US-20120035192-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-7985754-B2 | Selective antagonists of A2A adenosine receptors | TROVIS PHARMACEUTICALS, LLC (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090118309-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2009-05-07 | — | — | US | disclosed |
| EP-2041136-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | PGXHealth, LLC (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008011007-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | PGXHEALTH, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309774-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885TPSAB1 836/4885TPSD1 970/4885 |
| US-20090118309-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885TPSAB1 836/4885TPSD1 970/4885 |
| US-20120035192-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885TPSAB1 836/4885TPSD1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.